Peer-Reviewed Literature Synthesis

Major Depressive Disorder Biomarker Atlas

Molecular alterations reported in Major Depressive Disorder compared to healthy controls, from peer-reviewed literature.

Spontaneous remissionRelapse in 19-45% within 1 year of antidepressant discontinuation after remission; relapse risk ratio (off-medication…
Best-intervention remission55-80% remain relapse-free at 1 year after well-managed discontinuation; psychotherapy (CBT) achieves comparable…
Gap sizeModerate; narrows substantially over time for maintenance medication question
Primary barrierpractice
Full remission profile →

Literature Overview

Biomarkers below are included only where peer-reviewed literature explicitly reports the marker's direction in Major Depressive Disorder patients relative to a named comparison population — not inferred.

4
Curated markers
3
Categories

Searchable Alterations Database

Comparison populations are quoted as reported in the source literature (e.g. healthy controls, disease-matched patients).

Marker / TestDirectionCategoryvs. ComparisonClinical ContextKey Reference

Key References

Peer-Reviewed Literature

Nobis et al. 2020

DOI: 10.3390/jcm9123793 →
Peer-Reviewed Literature

Jarkas et al. 2024

DOI: 10.1016/j.bbi.2024.07.037 →
Disclaimer: Educational synthesis of peer-reviewed literature only — not medical advice. Markers are drawn from published disease-vs-comparison-population studies; inclusion here does not imply diagnostic or clinical validation. Consult a qualified healthcare professional for interpretation.

Part of the Open Source Medicine Foundation Network

Open Source Medicine Foundation The OSMF hub — advancing open-source biomedical research infrastructure, tools, and evidence synthesis.
SpikeProtein.site Database and research resource on SARS-CoV-2 spike protein biology, persistence, and clinical implications.
Vaccine Data Navigator Open-access navigation tool for vaccine adverse event reporting and surveillance data.
PACVS Research Summit Annual summit convening researchers, clinicians, and patients on PACVS science.